Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

TaiGen Biopharmaceuticals Holdings Limited (4157) AI Stock Analysis

TW:4157

TaiGen Biopharmaceuticals Holdings Limited

(TPEx:4157)

Select Model
Rating:52Neutral
Price Target:TWD 8.00â–¼(-3.50% Downside)
Action:initiatedcoverage
Date:11/09/26

Strong balance sheet is the key positive factor, but inconsistent cash generation and weak technical signals with price below moving averages are the main drags. High valuation multiples add further caution.

Positive Factors
Low financial leverageConservative financing reduces financial risk and preserves flexibility for research, regulatory work, commercialization, and partnering. A strong equity base also gives TaiGen greater capacity to manage uneven revenue cycles without relying heavily on additional borrowing.
Negative Factors
Inconsistent cash generationUneven operating cash flow makes reported profitability less dependable as a source of internally funded growth. Modest cash conversion and volatile free cash flow could constrain research, regulatory, and commercialization spending if earnings weaken again over the next several quarters.

TaiGen Biopharmaceuticals Holdings Limited (4157) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%TW:4157-11.15%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 5.88B
Dividend Yield
―
Average Volume (3M)
963.90K
Price to Earnings (P/E)
37.4
Beta (1Y)
0.55
Revenue Growth
530.40%
EPS Growth
―
Country
TW
Employees
52
Sector
General
Sector Strength
55
Industry
Biotechnology

TaiGen Biopharmaceuticals Holdings Limited Business Overview & Revenue Model

Company Description

TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a...

TaiGen Biopharmaceuticals Holdings Limited Financial Statement Overview

Summary

Balance sheet strength with low debt-to-equity below 0.07 supports stability, but volatile revenues, profits, and inconsistent cash flows typical of biotech milestone payments constrain the score.

Income Statement

58Neutral

Balance Sheet

85Very Positive

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue256.46M259.47M150.65M123.13M36.23M1.29B
Gross Profit236.06M223.83M134.52M111.69M32.49M1.28B
EBITDA121.00M86.87M-6.63M172.23M-200.37M928.34M
Net Income155.12M45.18M-38.58M136.73M-237.16M775.62M
Balance Sheet
Total Assets1.06B1.17B1.17B1.23B1.05B1.39B
Cash, Cash Equivalents and Short-Term Investments915.27M1.03B1.02B1.04B899.50M924.39M
Total Debt11.43M49.22M58.71M74.69M38.47M53.46M
Total Liabilities37.84M92.38M91.96M110.94M76.98M139.11M
Stockholders Equity1.02B1.07B1.08B1.12B970.03M1.25B
Cash Flow
Free Cash Flow-76.42M16.42M-175.78M65.00K-28.73M617.24M
Operating Cash Flow-73.58M20.93M-173.09M7.46M-21.27M629.07M
Investing Cash Flow154.95M83.37M-110.87M145.46M-84.95M-306.07M
Financing Cash Flow-98.43M-34.64M-17.40M-19.99M-15.84M-18.85M

TaiGen Biopharmaceuticals Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4157 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:4166TW:416670OutperformTWD 5.47B22.78――――
TW:1734TW:173464NeutralTWD 6.07B17.33―3.13%2.44%-3.96%
TW:4167TW:416760NeutralTWD 6.30B7.86―4.18%-0.05%64.82%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4157TW:415752NeutralTWD 5.78B37.38――530.40%―
TW:6785TW:678541NeutralTWD 5.11B-73.49―0.12%-57.57%-312.45%

* General Sector Average

Performance Comparison

-50%0%50%TW:4157TW:1734TW:4166TW:4167TW:6785TW:7754Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4157 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4157TaiGen Biopharmaceuticals Holdings Limited8.29-1.17-12.37%
TW:1734Sinphar Pharmaceutical Co. Ltd.30.151.896.71%
TW:4166Orient Pharma Co., Ltd.22.55-1.95-7.96%
TW:4167Savior Lifetec Corp.19.252.5715.39%
TW:6785Alar Pharmaceuticals Inc80.10-172.14-68.25%
TW:7754Annji Pharmaceutical Co., Ltd.69.4024.9055.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026